Sign In
Buy IDXX
$560.73
+9.91 (+1.80%)
At Close: Jun 03, 2026
IDEXX Laboratories to Release 2024 Fourth Quarter and Full Year Financial Results
04:15pm, Thursday, 16'th Jan 2025
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 fourth quarter and full year financial r
IDEXX Stock Suffers Due to Macroeconomic Issues and FX Woes
10:41am, Wednesday, 15'th Jan 2025
With sustained inflationary pressure, IDEXX may struggle to keep its cost of revenues and operating expenses in check.
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
10:46am, Thursday, 26'th Dec 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX
10:09am, Thursday, 19'th Dec 2024
Sustainability Roundtable Inc. announced Synopsys, IDEXX, and Juniper Networks as winners of the 2024 SBER Awards for standout leadership in sustainability
A Once-in-a-Decade Opportunity: 2 Magnificent S&P 500 Stocks Down 37% and 28% to Buy Before 2025
08:45am, Friday, 13'th Dec 2024
One of my favorite ways to add money to my portfolio is to invest in proven compounders with track records of delivering market-beating results after short-term pullbacks. This idea is especially true
Global Expansion to Support IDEXX Stock Despite Macroeconomic Issues
12:01pm, Wednesday, 11'th Dec 2024
IDEXX focuses on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth.
IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization
07:30am, Monday, 09'th Dec 2024
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that the Company's Board of Directors authorized an increase i
Should You Hold IDEXX Stock in Your Portfolio for Now?
11:15am, Friday, 22'nd Nov 2024
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
IDEXX Announces CFO Transition
07:30am, Thursday, 21'st Nov 2024
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective J
IDEXX Laboratories Q3: Weak End-Market Demand Continues
07:50pm, Sunday, 10'th Nov 2024
I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
04:11am, Wednesday, 06'th Nov 2024
Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.
A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback
09:53am, Tuesday, 05'th Nov 2024
Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today.
IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript
01:59pm, Thursday, 31'st Oct 2024
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participan
CORRECTING and REPLACING IDEXX Laboratories Announces Third Quarter Results
01:15pm, Thursday, 31'st Oct 2024
WESTBROOK, Maine--(BUSINESS WIRE)--In the 2024 Growth and Financial Performance Outlook section, second paragraph, second sentence should read: At midpoint, projected full year comparable operating pr
Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth
12:55pm, Thursday, 31'st Oct 2024
Idexx Laboratories Inc IDXX reported third-quarter adjusted EPS of $2.79, up 12% year-over-year, beating the consensus of $2.68.
